Objectives The treatment of wounds accounts for a considerable fraction of health expenses as well as serious socioeconomic problems. The use of natural substances stands out as a source of new therapeutic discoveries for the wound healing. Thus, this review compiled scientific findings on the applicability of carvacrol and thymol, or essential oils containing at least one of these compounds, for the treatment of wounds. Methods This review was performed at PubMed, SCOPUS, Web of Science databases using keywords as wound healing, thymol/carvacrol and essential oils. Thirteen studies were selected for discussion. Key findings Thymol/carvacrol was able to act in the three phases of wound healing. In the first phase, they showed modulatory effect of the inflammatory cytokines, oxidative stress and antimicrobial power. In the second phase, they promoted re-epithelialization, angiogenesis and development of granulation tissue. Finally, in the third phase, they improve the collagen deposition and modulated the growth of fibroblasts and keratinocytes. Conclusions These compounds present a high potential for the development of new therapeutic for wound repair. However, dose, efficacy and safety of these compounds for the treatment of wounds, as well as the mechanisms by which those effects can be observed, are challenges for future studies.
Introduction
Human skin wounds have been considered as a silent epidemic, once they affect a considerable number of people worldwide. They have been often associated with the ageing population and chronic diseases, such as diabetes and obesity. [1] For these reasons, a wound represents an important threat to global public health, due to high economic and social impacts, particularly the necessity of absenteeism at work, psychosocial changes and a decrease in the quality of life, demanding long-term, costly and complex treatments in some cases. [1, 2] From the biological point of view, wound healing is an important, multifaceted, physiological process governed by sequential and overlapping phases, which comprises a series of complex mechanisms activated after the injury. [3, 4] Failure to fully understand the molecular basis inherent in tissue repair and the lack of more accurate studies in experimental animals that can adequately configure human conditions corroborate the lack of adequate therapies and treatments for wound healing. [5] In this sense, the search for more effective and cost-effective therapeutic approaches for wound healing remains a challenge. In addition, medicinal plants have been used as a complementary, alternative and/or integrative therapy for several diseases worldwide. [6, 7] For this reason, bioactive products extracted from plants draw great scientific and commercial interests for the development of new drugs, since they stand out as an inexhaustible source of potentially active substances. [6, 7] In this context, essential oils (EO) composed of low molecular weight volatile components, such as monoterpene and sesquiterpenes, are inserted. The monoterpenes account for about 90% of the EO and are endowed with a wide range of biological and pharmacological properties. [8, 9] Carvacrol and thymol are monoterpenes widely found in essential oils of the genus Origanum. [10] These isomers of position ( Figure 1 ) have several antibacterial and antifungal activities [11] and also anti-inflammatory [12] and analgesic [13] effects. These properties make these compounds strong candidates for the development of products for tissue repair.
Thus, this systematic review aims at examining and synthesizing the cicatrizing potential of the monoterpenes thymol and carvacrol, and essential oils containing them. Therefore, the present study aims to answer the following question: Is Carvacrol, its isomer -Thymol -or the essential oil containing at least one of these compounds, a therapeutic potential for the development of biotechnological products for the management of wound healing?
Methodology
This systematic review was conducted on 9 May 2017 and updated on 20 February 2018 at the National Library of Medicine, Washington, DC, USA (MEDLINE-PubMed), SciVerse Scopus Elsevier (SCOPUS) and Web of Science, using different combinations of the following keywords: wound healing, wounds, thymol, carvacrol and essential oils ( Table 1 ). The structured search strategy was designed to include any published article evaluating wound healing using thymol or carvacrol or essential oils with at least one of them in its composition, independently. Year and language of publication were not established.
All electronic research titles and full-text articles were independently analysed by two reviewers (MFC and AOD), and the agreement between these reviewers was measured using the kappa statistics. Disagreements over the inclusion/exclusion of the study were resolved after a discussion and reach of a consensus between the reviewers, and the decision was supported by the assistance of a third reviewer (AGG).
The following inclusion criteria were applied: studies that performed wound healing tests in animal models, human, fibroblast cell tests and skin model using carvacrol, thymol or essential oils with at least one of them. The studies were excluded according to the following exclusion criteria: they did not have carvacrol or thymol alone or in mixtures composing essential oils, articles related to oral mucosa treatment and dental treatments, neoplastic wound, ocular tissue injury, review articles, meta-analyses, abstracts, conference articles, editorials/letters and case reports.
Data were extracted by one reviewer (MFC) using standardized forms and were verified by a second reviewer (AOD). The information extracted included data about the substance (carvacrol or thymol), formulation developed, wound model/type of cure, methods and tests of evaluation, posology, standard drugs, species/gender, results and proposed mechanisms of action, side/adverse effects.
In addition, checklists were used to measure study design quality and risk of bias through 07 and 16 points for clinical and preclinical studies, respectively. The higher the score achieved, the better the study profile. In order to verify the quality of the clinical study, the 'Clinical Studies Bias Risk' was used following the protocol used by Cochrane [14] with adaptations, and for the preclinical studies, the models suggested by Ara ujo-Filho et al. [15] and Farrell et al. [16] were used. The topics mentioned were used to evaluate the main aspects of the study design that contributed to its quality, such as group randomization, dose of the product used, cytotoxicity/adverse effect, macroscopic and histological evaluation of the wound, use of reference product between groups and blind evaluation of the results for preclinical studies. As for the clinical study, random sequence generation, concealment of allocation, blindness of participants and professionals, evaluation of blindness outcome and other sources of bias were evaluated. From the evaluation of these criteria, the studies were considered as having higher methodological quality when they reported randomization, blindness and evidence of pharmacological action through cellular or molecular biology techniques, histological and macroscopic evaluation of the wound. We also analysed the sources of funding for the studies present in this review.
Results
The initial search identified 848 articles, of which 78, 501 and 269 were found in MEDLINE-PubMed, SCOPUS and WEB OF SCIENCE, respectively. After the removal of duplicates and the selection of relevant titles and abstracts, 89 articles were submitted for the analysis of materials and methods. Nine articles fulfilled the established inclusion and exclusion criteria and, in a new hand search, four studies also met these criteria, totalling 13 articles. The agreement between these reviewers presented a coefficient of 0.852 (P < 0.001), indicating a near-perfect agreement. A flowchart illustrating the progress of the selection and the article number at each stage is shown ( Figure 2 ). Tables 2 and 3 present an overview of the 13 articles included in this study.
Thymol
In this review, 10 articles were found on the healing capacity of thymol alone (n = 4) or composing essential oils (n = 6). The first finding was published by Dursun et al., [17] who evaluated the effect of the thymol-rich Thymus oil diluted in olive oil (1 : 1; TO group) on burninduced wounds. The authors observed that on the 7th day there was a reduction in the acute inflammatory response, thickening of the dermis and reduction of necrosis areas. On the 21st day, re-epithelialization and granulation were observed for all treatments, as well as an increase of collagen fibres and capillaries. In addition, after the inflammatory phase of the wound, the thymus oil-treated rats reduced the levels of nitric oxide (0.382 AE 0.239 lm/ mg.protein), a reactive species that modulates oxidative stress in the initial stage of healing. However, the sulfadiazine silver group and the non-treated group presented higher levels of nitric oxide, 0.541 AE 0.208 and 0.662 AE 0.203, respectively.
Afterwards, Khorshid et al. [18] performed in vivo and in vitro tests using EO from Plectranthus tenuiflorus (thymol 85.3%). EO (0.005-0.01%, w/v) and pure thymol (0.0005%, w/v) stimulated growth of human skin fibroblasts at concentrations of 48-72 h. On the other hand, inhibitory effects were observed at higher doses of EO (IC 50 = 1 9 10 À2 ) and pure thymol (0.0063% w/v) in 24 h. It was found that the formulation tested containing 10% of EO in absolute ethanol was effective for the second intensity wound repairs in rats, promoting the reduction of 91.23% on the 12th day and 99.68% on the 16th day, with complete healing on the 18th day, 97.75% for the nontreatment group in the same time period, which presented complete closure after 22 days. Besides, on the 14th day, it was observed that EO promoted complete re-epithelialization and reappearance of cutaneous appendices. Subsequently, Akkol et al. [19] prepared extracts of Achillea biebersteinii using various types of solvents, of which nhexane presented 0.24% thymol in its composition. An ointment with 1% of this extract optimized the healing process and showed a contraction of 61.7% on the 8th day, 84.2% on the 10th day, comparable to the standard group of drugs (Madecassol â : 100%), on second-intention wound model. Both groups demonstrated epidermis and mature hair follicles, keratinization and presence of fibroblasts in the dermis. The ointment presented tensile strength also similar to Madecassol â (near to 40.1%) on first-intention wound model. The study showed that the healing power may be associated with the synergistic effect of various secondary metabolites, including monoterpenes, such as thymol, and sesquiterpenes. A year later, Riella et al. [12] developed a collagen film using 10% thymol (COLTHY) that promoted a reduction of inflammatory response, more mature granulation, formation of new blood vessels and dense deposition of collagen fibres on the 7th day. On the 14th day, there was a more expressive reduction of leucocytes and, consequently, Marzouk et al. [25] a lower inflammatory response to COLTHY and COL groups (collagen film without thymol), differently from the control group (undressed wounds). Besides, COLTHY promoted an almost complete closure (100%) on the 14th day, an effect that was not observed in COL and control groups. On the 21st day, animals of all groups presented 100% of wound closure. A higher rate of contraction of the lesions, better granulation and presence of dense collagen with regularly disposed fibres were observed in the COLTHY group. These findings in the COLTHY group suggest that the thymol-containing formulation is capable of enhancing the modulating effect of fibroblasts and, consequently, increasing the collagen deposition in the wounds, whereas the fibroblasts are responsible for the synthesis and degradation of collagen.
In the following year, Karami et al. [20] developed a formulation of polypropylene (PCL) and polylactic acid (PLA) (50/50) containing 1.2% v/v thymol. This preparation was able to improve the cicatricial process of secondintention wounds, presenting 92.4% of closure in 14 days and re-epithelialization better than did Comfell plus â , a positive control used that presented closure percentage of 87% and 68% in the negative control in the same period. In addition, the thymol-containing formulation was found to inhibit the growth of Staphylococcus aureus and Escherichia coli, with inhibitory zones of 10.4 and 7.8 mm, respectively.
Oliveira et al. [21] applied EO of Lippia sidoides Cham. (Thymol: 70.97%, Carvacrol: 0.30%) on intact and abrasion-damaged skin, in addition to evaluating the effect of this oil on a second-intention wound model. The results of intact skin irritation showed that the topical application of L. sidoides EO promoted inflammation in a dose-dependent manner. The oil at concentrations of 100% and 50% promoted irritating effects on the skin of the mice, characterized by increasing thickness, oedema and erythema, loss of hydration and elasticity of the skin. On the other hand, low concentrations (6% and 12%) presented irritant effects after 7 days of treatment, inducing mild erythema and oedema, thus indicating a slight irritation. In the wound healing protocol, ointment containing the essential oil (6% and 12%) induced oedema and exudation up to day 5 and complete healing in 21 days (Wound contraction: 94.18 AE 1.97% and 93.88 AE 3.89% to 6% and 12%, respectively), similarly to the reference group Clostebol (acetate clostebol and neomycin sulfate): wound contraction 93.84 AE 3.48%. In this study, it was also demonstrated that this essential oil does not seem to change the COX-2 and VEGF expression on day 7.
Mollarafie et al. [22] developed a chitosan film containing 0.5% pure thymol (99.5%) and demonstrated that in vitro tests. Thymol was able to increase fibroblast cell growth significantly in a concentration ratio of 2/4 (100 ll cells) with percentage of cells alive after MTT assay of 273%.
More recently, Connell et al. [23] developed a hyperosmotic nanoemulsion (HNE) with different concentrations of thymol (0.01%, 0.03%, 0.063%) and tested in a swine model of contaminated wounds. They found that HNE accelerated the haemostasis for 24 h after surgery in comparison with the control group (without treatment) that presented bleeding on day 3. However, there were no significant changes in the wound size between the groups. HNE also demonstrated a higher level of moisture, in addition to the development of a dense layer of fibrin covering the dermis. On the 7th day, HNE re-epithelized approximately 94.29%, 95.72%, 98.58% and 91.99%, in concentrations of 0.0%, 0.01%, 0.03% and 0.063%, respectively. During the same period, the untreated control group reepithelized 93.26%. All wounds were healed on the 14th day. Every wound was contaminated by inoculating 5 9 10 7 CFU of S. aureus, E. faecalis, E. coli and C. albicans and the results showed that HNE with thymol reduced bacteria CFU when compared to the control group. This reduction was more expressive in the HNE with highest thymol concentration (0.063%), which reduced the bacteria CFU in 91.5%.
The preclinical study recently published by Pivetta et al. [24] developed a gel of carbopol containing nanoencapsulated thymol (50% w/w). They tested cytotoxicity in human keratinocytes, noting that nanoencapsulated thymol maintained cell viability above 80% and could then be considered as non-cytotoxic. Interestingly, free thymol at the 12.5-lM concentration appeared to stimulate the growth of keratinocytes, promoting cell viability greater than 100%. In contrast, concentrations of free thymol greater than 200 lM reduced the cell viability below 60%. This effect was reverted by nanoencapsulated thymol. Besides, the formulation containing thymol reduced the inflammatory response in different models of skin inflammation.
The only clinical study included in this review was conducted by Marzouk et al., [25] a randomized, single-blinded clinical trial with 60 postpartum women undergoing episiotomy. The authors developed a formulation of lavender oil and thymol (1 : 1 v/v) and, after that, started a treatment twice daily during 7 days. On the 7th postpartum day, the women were evaluated using REEDA scale, which evaluated hyperaemia, oedema, ecchymosis, discharge and border approach in episiotomy, and VAS (visual analogue scale). Women in the placebo group (saline solution in water) had a worse REEDA score (3.93 AE 3.65) compared to the treatment group (2.03 AE 1.77), with significant reduction of hyperaemia (P = 0.027), exudation (P = 0.016) and oedema (P = 0.027). Also, dyspareunia was lower in women in the lavender/thymol group compared to the placebo group (2.7 AE 1.5 vs 5.3 AE 2.7). However, ecchymosis and approximation did not show significant differences between the groups.
Carvacrol
For the carvacrol, three articles were found on its cicatrizant properties. S€ untar et al. [26] developed an ointment containing a mixing of four ointments at the same proportion, among them: Hypericum perforatum ointment at 10%, olive oil ointment at 10%, Oregano ointment at 12.5% (mixing of Origanum majonara L. and Origanum minutiflorum O. 1 : 1, composed mostly of 70% carvacrol) and Salvia etrilobae aetheroleum ointment at 7.5%. This ointment was applied topically to the wound once a day and promoted 45.2% tensile strength on the 10th day in a firstintention wound model, close to Madecassol â (51.3%). In the second-intention wound model, the ointment presented 45.9%, 74.8% and 91.8% contraction rates on days 8, 10 and 12, similar to Madecassol â (42.7%, 70.8%% and 100%, respectively). Besides, in this model, the ointment was able to improve the remodelling, particularly in the reepithelialization and in the reduction of inflammation. The formulation demonstrated collagenase activity, but without elastase activity in vitro, and also exerted bactericidal and candicidal activity. Three years later, S€ untar et al. [27] studied the healing potential of some plants commonly used in Turkey, among them: Laurus nobilis (carvacrol 0.1%) and Lavandula angustifolia ssp. Angustifolia (thymol 0.1%). In the first-intention wound model, the ointments developed with the essential oils of these plants presented better tensile strength (27.2% and 30.5%, respectively, on day 10) than did the negative control (9.3%). Animals treated with the standard drug (0.5 g Madecassol â ) presented tensile strength of 51.9% in the same period. The formulations of Laurus nobilis and Lavandula angustifolia presented high contraction percentage of second-intention wound model (42.22% and 39.05%, respectively, in 12 days) compared with the vehicle (treatment with ointment base only), which promoted 7.89% of contraction. Madecassol â showed a better contraction of wound of 100.00% in the same period. It was demonstrated that Madecassol â and then the ointments containing L. angustifolia and L. nobilis showed the best remodelling and reepithelialization. Subsequently, Gunal et al. [28] evaluated the healing effect of a dressing containing carvacrol (12.5%) diluted in sunflower oil (2%) for 12 days. The results showed that carvacrol significantly reduced the surface of the lesion on day 12 (P = 0.014), promoting changes in granulation tissue thickness and lesion depth (P = 0.002) compared to the control, which caused inferior granulation (P = 0.008). In addition, it was observed that carvacrol was able to modulate the release of tumour necrosis factor-a (TNF-a), transforming growth factor (TGF-a) and interleukin 1b (IL-1b) throughout the tissue repair.
Quality of studies and risk of bias
Regarding the methodological analysis of the quality of the studies, only one [12] preclinical study was considered as having high quality, according to our criteria, for having reported randomization of animals in the control and experimental groups, as well as blindness in the investigators' analyses. The calculation of sample size was not reported or was unclear in eight preclinical studies of the 12 surveys, and the number of animals per group varied widely (Figure 3 ). On the other hand, the clinical study [23] reported randomization and simple blindness. However, the evaluations of this same study were performed subjectively, without presenting molecular analyses. Among the 13 articles selected, only 06 reported financial support for the development of the study, of which five were funded by the research institution, [17] state (n = 3) [12, 19, 22] or national development agencies (n = 2). [12, 17] Only one study [21] was funded by a company with a statement of potential benefit from the results of this research. In addition, 03 articles did not receive financial support [17, 21, 26] and 04 studies did not present this information. [17, 20, 24, 25] 
Discussion
In a nutshell, from the 13 selected studies, most of the researches were conducted in Turkey (38.4%), followed by Brazil (23.0%), Iran (15.3%), Saudi Arabia (7.6%), India (7.6%) and Egypt (7.6%). This fact can be explained by historical and geographic factors, since medicinal plants have been used in developing countries for thousands of years, many of which are native to the land or were introduced during the colonization process. In addition, the WHO (World Health Organization) [29] estimates that about 65-80% of the population living in developing countries depends on traditional healthcare systems. Therefore, the intense use of plants in the referred regions stimulates the development of research in this area, which can be evidenced by the constant publication of studies over the last 8 years (Tables 1 and 2 ).
In the selected articles, the experimental models used were second-intention (50.0%), first-intention (8.3%) and burn wound models (8.3%) developed in animals. In general, the excision wound model was the most used (75.0%) because it is fast and cheap. [30] Of the 11 studies performed on experimental animals, only one was performed with pigs, an animal model that presents anatomical and physiological similarities closest to the human skin. [23] The other 10 studies were conducted in rodents, such as rats and mice. Besides, 8.3% used in vitro protocols for growth and cytotoxicity evaluation in cutaneous tissue cells, such as fibroblasts and keratinocytes.
In this review, we verified the use of essential oils and pure compounds, in most cases composing pharmaceutical formulations such as solutions, ointment, polymers, collagen films, chitosan films and nanostructured systems. In fact, the physical-chemical properties of monoterpenes, such as carvacrol and thymol, researched herein, can limit their use in the pharmaceutical industry. For this reason, technological strategies have been applied to the development of products that enable the use of these compounds safely and effectively. [31, 32] Likewise, we also observed that extracts and essential oils containing these monoterpenes have been often studied to improve cicatrization (n = 6). Pure thymol also presented a significant number of publications (n = 6), while only one study used pure carvacrol.
However, a study published in the Federation of American Societies for Experimental Biology (FASEB) journal, referring to a work presented at the meeting of experimental biology societies held in 2015 (Experimental Biology 2015) in Boston, showed that carvacrol incorporated to chitosan films (0.5% or 1%) has a potential use on skin wound healing. [33] This formulation was able to reduce wound areas and oedema, induce earlier granulation tissue formation and increase cell proliferation and epithelization in rats with a second-intention wound.
Wound healing is an evolutionary, complex and multicellular process. Sun et al. [34] characterized the healing process in five phases: coagulation, inflammation, proliferation, wound contraction and remodelling. Further studies have been carried out to periodically reclassify the phases of healing in three: inflammatory, proliferative and remodelling. [35] In a didactic way, we will perform our analysis comparing the power of action of the monoterpenes carvacrol and thymol with the three healing phases mentioned above.
The first phase is initially marked by haemostasis, which is characterized by vasoconstriction, platelet aggregation and activation of coagulation systems. [36] A few hours after the injury, the inflammatory process is established, with the migration of neutrophils accompanied by the release of cytokines, prostaglandins and free radicals by the tissue, migratory cells and platelet, which also release growth factors, stimulating cell proliferation. [4, 37] In this review, thymol, carvacrol or essential oils containing them were able to modulate the release production of reactive species, as nitric oxide, [17] pro-inflammatory cytokines such as TNF-a and IL-1b and growth factors such as TGF-1b [28] involved in the initial stages of the healing process. In fact, other studies reinforce these results. Carvacrol has been shown to inhibit the expression of IL-4, IL-17 and IL-1b, [38, 39] COX-2 [39] and TNF-a. [40] In addition, it promoted the increase in IL-10, an important antiinflammatory cytokine, as demonstrated by Lima et al. [39] Studies with both isomers also reveal that these compounds singly reduce IL-1b, IL-6, IL-8, IL-17, [41] IL-25 and IL-33.
[42] Similar findings were reported by Meeran et al. [43] who demonstrated that thymol is able to decrease the expressions of TNF-a, IL-6 and IL-1b, attenuate the lipoperoxidation and reduce inflammation. From these mechanisms, carvacrol and thymol are able to attenuate the leucocyte migration characteristic of the first phase of tissue repair, as demonstrated by Riella et al. [12] and Karami et al. [20] for thymol, and by Pina et al. [44] and Guimarães et al. [40] in other experimental models for carvacrol. In fact, the anti-inflammatory potential of carvacrol has been evaluated in two recent clinical trials, [45, 46] indicating that its clinical use is effective for the management of inflammatory conditions. Subsequently, the proliferative phase begins, which is divided into four stages: re-epithelialization, angiogenesis, formation of granulation tissue and deposition of collagen. [47] Through the histological analyses carried out in the studies involved in this review, carvacrol and thymol have been shown to stimulate re-epithelialization, angiogenesis, formation of granulation tissue and deposition of collagen fibres. This effect may be associated with the ability of these compounds to modulate the initial inflammatory phase, since the evolution of granulation tissue into scar formation is closely related to chronicity of the inflammatory infiltration during wound healing. [48] In addition, other studies have shown that carvacrol induces angiogenesis by increasing vascular endothelial growth factor (VEGF) expression. [49] Besides, both monoterpenes also increase TGF-b in vitro. [50] The third stage of healing is the most clinically relevant and involves remodelling/maturation. This phase has the fibroblasts as main agents, which produce the collagen and deposit it in a structured way, promoting resistance. [12] Collagenization was seen in the treatment of wounds with thymol. [12, 18, 22] In addition, thymol is able to promote complete replacement of type III to type I collagen in 14 days, [12] indicating a normal, dynamic collagenation as previously reported in other experimental wound healing studies with red propolis and usnic acid. [51, 52] These findings are reported by other studies with thymol and carvacrol, which demonstrate that both isomers stimulate the production of collagen. [53, 54] Therefore, the discoveries mentioned suggest that these monoterpenes may play an important modulating effect on fibroblast metabolism and collagen synthesis.
Matrix metalloproteinases (MMP) also present an important role in the remodelling phase of wound healing, as shown by R€ ohl and Murray [55] in a depth review of MMP. However, high levels of some MMP as MMP9 seem to contribute to the extracellular matrix (ECM) degradation in non-healing wounds. [56, 57] In fact, the transient and local expression of MMP9 in acute wounds is necessary to promote the healing process; high levels are detrimental, as it occurs in diabetic foot ulcers, venous leg ulcers and pressure injuries. [55, 58] Similarly, high levels of MMP2 in venous leg ulcers and diabetic foot ulcers [58] also seem to hinder the wound healing. In this context, carvacrol and thymol are also able to downregulate MMP9 and MMP2 in several experimental conditions [41, [59] [60] [61] [62] and these effects can be interesting to the management of chronic wounds.
However, it is hard to know the exact molecular targets of these compounds, once studies with investigation of the mechanism of action are scarce. Of 13 articles included in this review, only three evaluated some molecular target. [17, 21, 28] Through these studies, it is possible to suggest the modulation of redox balance, inflammatory cytokines and growth factors. Only one study [21] did not observe any effect of the compound tested (EO of Lippia sidoides containing Thymol 70.97% and carvacrol 0.30%) on COX-2 and VEGF expression on the 7th day of second-intention wound. On the other hand, previous studies had shown that thymol can attenuate the expression of COX-2 as well as iNOS by being able to block the phosphorylation of IjBa, NF-jB p65, ERK, JNK and p38 mitogen-activated protein kinases (MAPKs). [63, 64] This contradiction can be justified by the action of the other compounds of the essential oil, which can antagonize the effect of thymol. For VEGF, however, other studies reinforce the ability of thymol to inhibit the expression of this growth factor. [65] Another property that made these molecules strong candidates for wound healing is their antioxidant activity. The oxidative stress is a factor that contributed to the healing of acute wounds in all phases. [66] However, in chronic conditions, the redox balance needs to be improved. [66, 67] In this sense, compounds as carvacrol and thymol, which present a pronounced antioxidant effect, can contribute with the redox balance since they activate antioxidant systems, as GPX, CAT and SOD [68, 69] ; reduce iNOS [64, 70] ; modulate reactive species; and decrease the damage promoted by them. [40, 71] Histological analyses showed that the monoterpenes acted in all the cicatricial phases, similar to the parameters previously mentioned. In the inflammatory phase, there is the migration and modulation of fibroblast cells, [12, 18, 24] formation of exudates and the presence of inflammatory cells, increased vascularization, [17, 26] activation of the coagulation cascade and the presence of keratinocytes. [21] Previous studies have shown that the migration of keratinocytes marks the onset of wound contraction force due to the activation of myofibroblasts. [72] The increase in the granulation tissue and reduction of the depth of the lesion area and neoangiogenesis highlight the second stage of healing, mentioned in several studies present in this review. [17, 18, 25, 26] This phase is characterized by an intense increase in fibroblasts and vascular neoformation. [73] The presence of mature hair follicles, [12, 17] which highlights the remodelling phase, results in the formation of the epithelium and contraction of the wound due to cell proliferation. [74] These isomers also present high antimicrobial potential. Thymol may inhibit the growth of Staphylococcus aureus, Escherichia coli, [20] S. aureus, E. coli and Pseudomonas aeruginosa, [22] S. aureus, Enterococcus faecalis, E. coli and Candida albicans. [24] Supporting this idea, Altiok et al. [75] showed the power of the thyme oil against S. aureus, E. coli, P. aeruginosa and Klebsiella pneumoniae. Carvacrol also has antimicrobial properties inhibiting the growth of S. aureus and E. coli, [74] antifungal [73] and antiviral agents, [72] corroborating with S€ untar et al., [76] who show the effect on the growth of P. aeruginosa and S. aureus.
Thus, due to this vast pharmacological and biological action, carvacrol and thymol are strong candidates for the development of future drugs for the management of tissue repair. Figure 4 summarizes all of the data reported until here. One can realize that thymol and carvacrol are able to modulate all phases of wound healing, presenting an important role in the first phase. Other studies are needed to understand the molecular mechanisms by which these monoterpenes can act in the second and third phases.
Thus, the studies reviewed here suggest that these compounds are strong candidates for the development of new wound treatment products. However, we managed to verify that the studies did not present a standard posology of treatment. Concentrations ranged from as low as 0.01% to as high as 50%. In addition, in some studies a single topical application was performed, while in others the treatment was reapplied at intervals ranging from 5 to 21 days (Tables 1 and 2 ). Thus, it is necessary to adjust the doses used in order to ensure the safety of the use of these compounds.
Even with so many variations, all studies have shown that these monoterpenes or essential oils containing at least one of them are capable of improving tissue repair. In fact, considering 06 studies that used a standard drug, three showed an effect much similar to the drug, [19, 21, 26] in two studies the test compounds showed better effect than did the positive control, [17, 20] and only one demonstrated that these compounds were less effective than the drug. [27] In this last case, the low concentration of the test compound (carvacrol 0.1%) can be associated with the result observed. It is worth noting that the absence of standard drugs in other studies (n = 4) makes it difficult to present a more accurate analysis of the real benefit of the natural product tested.
Besides, side effects were hardly reported in the studies selected for this review. Only Oliveira et al. [21] demonstrated that L. sidoides EO at high concentrations (100% and 50%) had irritating effects on the skin of mice, which was shown to be less aggressive at low concentrations (12%). In fact, studies on the toxicity of these compounds are still scarce, [77] especially when administered topically.
Finally, these limitations associated with the bias identified in this review are possible justifications for the low number of clinical trials found in this research (n = 1). Therefore, preclinical studies need to be improved in order to optimize the use of experimental animals and provide safer and more accurate information on the pharmacological effects of natural wound healing products, such as the monoterpenes carvacrol and thymol.
Conclusion
For more than a decade, researchers have studied the potential of the monoterpenes carvacrol and thymol for wound healing, through in vivo and in vitro assays. These compounds present high potential for the development of new therapeutic alternatives for wound repair, and they have already started to be tested in humans. However, the determination of the doses and formulation ideas, and the effectiveness and safety of the use of these compounds or essential oils containing them for the treatment of wounds, as well as the mechanisms by which these effects can be observed, stand out as the challenges for future studies.
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